Business Wire

Biolog-id Branches out to the United States with a New Operational Center in Atlanta

Del

Biolog-id, a world leader in connected health solutions, today announced the establishment of its U.S. operational center in Atlanta. This new site will enable Biolog-id to continue the growth of its presence in North America and offer its business solutions in the biggest health market in the world.

Biolog-id LLC’s offices are located in Alpharetta, 15 minutes north of Atlanta, Georgia. Pierre Parent, President of Biolog-id, has named Amit Mayer as the General Manager of the subsidiary.

Amit Mayer is an experienced manager with a variety of experience in the health, innovation, marketing and education domains. As an entrepreneur, consultant, teacher and businessman, Amit has worked for high-profile businesses and organizations throughout the world and is particularly interested in the healthcare sector. He has been based in Atlanta for the last 5 years.

“Biolog-id has developed unique expertise in connected health solutions and has created a ground-breaking innovation which enables the reliable tracking of sensitive therapeutic products (red blood cell concentrates, platelets, plasma, and chemotherapy products), and ensures their safe administration to patients. By establishing a permanent presence in the US, Biolog-id aims to offer local clients quality support for its product offerings in America. This operational center will manage sales, sales support, operations and R&D. “Biolog-id is poised to establish itself in the US market and we are convinced Amit is the right person to make this a success”, says Pierre Parent.

“Biolog-id’s solutions are based on the Internet of Things (IoT), which improves the quality and safety of medical procedures and patient care by ensuring that the right product is administered to the right patient, and allowing healthcare professionals to devote more time to patient”, adds Amit Mayer. “They can be entirely integrated into existing work processes and provide significant financial savings by reducing product loss and optimizing the supply chain (reducing stock, remote management with no manual handling, etc.). In addition, Biolog-id’s solutions also help improve working conditions for healthcare professionals by relieving them of time-consuming administrative and logistical tasks. This transatlantic site is testament to our aim to make use of all our synergies to provide the North-American market with a one-of-a-kind service offering. By forming a team that is focused on adapting solutions to the specific features of blood transfusion centers, hospital blood banks and pharmacies responsible for injectable products, Biolog-id aims to provide ad hoc solutions with significant added value, enabling our rapid growth in North America.”

About Biolog-id
Biolog-id was founded in 2005 based on a pioneering concept: using RFID technology to identify, track and manage sensitive health products (red blood cells, plasma, platelets, chemotherapy products). This ground-breaking innovation enabled the development of a totally unique product: the “Biolog solution” and its intellectual property rights, currently amounting to 100 or so international patents.
The company’s corporate office is located in Paris and its manufacturing and product and customer support facility is situated in Bernay in the Normandie region of France. It currently employs approximately 80 people and is continuing its recruitment plan both in France and abroad. www.biolog-id.fr

Contact information

Biolog-id
Amit Mayer, +1 404 953 3169
amit.mayer@biolog-id.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 18:00Pressemelding

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)

Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 14:33Pressemelding

Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55Pressemelding

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 12:57Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl

Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation16.11.2018 08:00Pressemelding

Dimension Data, the USD 8 billion global technology integrator and managed services provider, today announced that its Global Delivery Centre (GDC) in Prague has won the 2018 ABSL Diamond award for Business Innovation. The main purpose of this centre is to provide innovative, global service delivery capabilities and deep technical expertise to support our clients. The ABSL Diamond awards recognise companies that implement innovative projects, enhancing their business and strengthening the position of the business services sector. Every year, the aim is to identify successful activities in this sector and promote best practices, ultimately encouraging and inspiring others to follow suit. The ABSL celebrates initiatives that push business services forward and stand out as exemplary projects. Bill Padfield, Group Chief Operating Officer for Transformation and Services at Dimension Data, said: “Winning another award for our Support Services is a fantastic achievement. This time the ABSL Di